[Effects of lovastatin in primary hypercholesterolemia].

Abstract

Lovastatin, a potent inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme-A-reductase, was investigated in a placebo-controlled trial of 26 primary hypercholesterolemic subjects. Drug dosage varied from 20 to 40 mg/d in a single dose on a 12 weeks treatment period. Average plasma cholesterol reduction levels were 17 and 31%, and LDL-cholesterol 24 and 41% on 20 and 40 mg/d respectively. High-density lipoprotein and triglycerides levels did not change significantly. Similar mean decreases in total plasma cholesterol and LDL-cholesterol levels were observed in hypercholesterolemics irrespectively of being of familial origin or not. No serious clinical and laboratory abnormalities were observed. In this study, lovastatin was a well tolerated and effective agent for the treatment of non familial and heterozygous familial hypercholesterolemia.

• Authors: E R Nakandakare, R C Garcia, J M Carré, C V Zerbinatti, H C Oliveira, E C Quintão
• Journal: Arquivos brasileiros de cardiologia (Arq Bras Cardiol) Vol. 52 Issue 5 Pg. 291-5 (May 1989) ISSN: 0066-782X [Print] Brazil
• Vernacular Title: Efeitos da lovastatina na hipercolesterolemia primária.
• PMID: 2690785 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Cholesterol, LDL
• Cholesterol
• Lovastatin

Topics

• Adolescent
• Adult
• Aged
• Cholesterol (biosynthesis, blood)
• Cholesterol, LDL (blood)
• Clinical Trials as Topic
• Female
• Humans
• Hypercholesterolemia (drug therapy)
• Lovastatin (administration & dosage, therapeutic use)
• Male
• Middle Aged